The regenerative power of stem cells

Research Updates

While treatments for arterial blockages have previously been very limited, our new stem cell research is demonstrating that it’s actually possible for the body to grow new blood vessels. Not only that, these blood vessels can substantially increase blood flow. 

Having successfully demonstrated this in the lab, the Cell Therapeutics Group is continuing to build an understanding of the method, which is providing hope for millions of people worldwide.

The process involves introducing blood vessel lining cells derived from induced pluripotent stem cells, known as ISPCs. The ISPCs are adult skin cells ‘reprogrammed’ to become other cell types, meaning they are not embryonic stem cells taken from unborn babies. This is just some of the awe-inspiring ork taking place every day at the Heart Research Institute.

The Cell Therapeutic Group’s overall focus is to develop novel therapies targeted against atherosclerosis (arterial blockages) and its consequences, namely the reduction in blood flow to the heart and periphery, leading to heart attack and stroke.

Their treatment aim is to bypass arterial blockages by stimulating new blood vessel growth, to restore blood flow to affected regions.

Previous
Next

Related news

New drug hope to target silent killer

An exciting new treatment for very high blood pressure is on the horizon after a world-first discovery by Heart Research Institute scientists, who have uncovered a brain chemical instrumental in triggering hypertension, the so-called silent killer responsible for the deaths of thousands of Australians each year.

The researchers are optimistic the results, published this week in the American Journal of Physiology-Heart and Circulatory Physiology, will ultimately lead to a powerful new treatment that blocks a neurotransmitter and frees patients from the dangers of hypertension. 

Read more

Gout Drug Mends Broken Hearts

A drug used to treat arthritis has been found to clear clogged arteries in heart attack survivors, world-first HRI research shows.

The landmark discovery by Associate Professor Sanjay Patel, Leader of the Cell Therapeutics Group, and his team at the HRI paves the way for a cheap, simple and effective treatment regime that could protect thousands of heart patients from future attacks that might kill them or further damage their heart. 

Read more

Neutrophils in acute coronary syndrome

HRI researchers Dr Rahul Kurup and Associate Professor Sanjay Patel from the Cell Therapeutics Group recently published a review of the role of neutrophils in acute coronary syndrome. With abundant data demonstrating this role, this presents opportunities to develop novel diagnostic and prognostic biomarkers and therapeutic agents that specifically target neutrophils.
Read more